CDNA (CareDx, Inc.) Stock Analysis - Financials

CareDx, Inc. (CDNA) is a publicly traded Healthcare sector company. As of May 21, 2026, CDNA trades at $21.18 with a market cap of $1.06B and a P/E ratio of -132.13. CDNA moved +2.92% today. Year to date, CDNA is +6.76%; over the trailing twelve months it is +19.22%. Its 52-week range spans $10.96 to $32.97. Analyst consensus is buy with an average price target of $24.73. Rallies surfaces CDNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are CDNA's key financials?

CDNA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CDNA recently traded at $21.18. Market cap is $1.06B. P/E ratio is -132.13. Revenue is $412.82M.

CDNA Key Metrics

Key financial metrics for CDNA
MetricValue
Price$21.18
Market Cap$1.06B
P/E Ratio-132.13
EPS$-0.16
Dividend Yield0.00%
52-Week High$32.97
52-Week Low$10.96
Volume242
Avg Volume0
Revenue (TTM)$412.82M
Net Income$-8.19M
Gross Margin0.00%

CDNA Annual Financials

YearRevenueNet IncomeEPS
2025$379.81M$-21.35M$-0.40
2023$280.32M$-190.28M$-3.54
2022$321.79M$-76.61M$-1.44
2021$296.40M$-30.66M$-0.59

Latest CDNA News

Recent CDNA Insider Trades

  • Novack Jeffrey Adam sold 2.69K (~$55.58K) on May 5, 2026.
  • Hanna John Walter JR sold 10.28K (~$217.16K) on Apr 16, 2026.
  • Novack Jeffrey Adam sold 4.44K (~$91.29K) on Feb 3, 2026.

CDNA Analyst Consensus

6 analysts cover CDNA: 0 strong buy, 2 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $24.73.

Common questions about CDNA

What are CDNA's key financials?
CDNA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CDNA recently traded at $21.18. Market cap is $1.06B. P/E ratio is -132.13. Revenue is $412.82M.
Is CDNA research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CDNA. It does not provide personalized investment advice.
CDNA

CDNA